Cure My Disease

Don't miss your cure!

Log in / Sign up

New drug aims to tame overactive thyroid in Graves' disease

NCT ID NCT07682896

Recruiting now Disease control Sponsor: Yarrow Bioscience, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This phase 2 trial tests an experimental drug called YB-101 in people with Graves' disease, an autoimmune condition that causes an overactive thyroid. The study will see if YB-101 can help normalize thyroid hormone levels and allow patients to stop taking anti-thyroid medications. Participants receive either YB-101 or a placebo injection over 24 weeks, with safety and effectiveness monitored closely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: YB-101
What this could lead to: If successful, YB-101 could offer a new way to control thyroid function in Graves' disease, potentially reducing the need for anti-thyroid drugs.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply to everyone. The drug may cause side effects or fail to improve thyroid function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAVES' DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Graves disease hyperthyroidism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAVES' DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Site 100
RECRUITING

Amarillo, Texas, 79124, United States
Site 101
RECRUITING

Humble, Texas, 77346, United States
Site 103
NOT_YET_RECRUITING

Sacramento, California, 95817, United States
Site 104
NOT_YET_RECRUITING

Columbus, Ohio, 43201, United States
Site 105
NOT_YET_RECRUITING

Torrance, California, 90502, United States
Site 106
NOT_YET_RECRUITING

Fort Worth, Texas, 76132, United States
Site 107
RECRUITING

Livonia, Michigan, 48152, United States
Site 108
NOT_YET_RECRUITING

Omaha, Nebraska, 68198, United States
Site 109
NOT_YET_RECRUITING

Miami Lakes, Florida, 33016, United States
Site 110
NOT_YET_RECRUITING

Houston, Texas, 77095, United States
Site 111
NOT_YET_RECRUITING

San Francisco, California, 94143, United States
Site 112
NOT_YET_RECRUITING

Gilbert, Arizona, 85297, United States
Site 115
NOT_YET_RECRUITING

Palm Harbor, Florida, 34684, United States
Site 116
NOT_YET_RECRUITING

San Antonio, Texas, 78233, United States
Site 117
RECRUITING

Conroe, Texas, 77384, United States
Site 118
NOT_YET_RECRUITING

Macon, Georgia, 31210, United States
Site 119
NOT_YET_RECRUITING

Chesapeake, Virginia, 23321, United States
Site 120
NOT_YET_RECRUITING

Orchard Park, New York, 14127, United States
Site 121
NOT_YET_RECRUITING

La Mesa, California, 91942, United States
Site 122
NOT_YET_RECRUITING

Bowling Green, Kentucky, 42103, United States
Site 123
NOT_YET_RECRUITING

Sarasota, Florida, 34239, United States
Site 124
NOT_YET_RECRUITING

Sayre, Pennsylvania, 18840, United States
Site 125
NOT_YET_RECRUITING

Orange, California, 92868, United States
Site 126
NOT_YET_RECRUITING

Flint, Michigan, 48532, United States
Site 127
NOT_YET_RECRUITING

El Paso, Texas, 79935, United States
Site 128
NOT_YET_RECRUITING

Edinburg, Texas, 78539, United States
Site 129
NOT_YET_RECRUITING

Niagara Falls, New York, 14304, United States
Site 130
NOT_YET_RECRUITING

Phoenix, Arizona, 85006, United States
Site 150
NOT_YET_RECRUITING

Melbourne N., Victoria, 3051, Australia
Site 151
NOT_YET_RECRUITING

East Melbourne, Victoria, 3002, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.